Complete remission of metastatic renal cell carcinoma to the bone with sunitinib

Target agents such as tyrosine kinase inhibitors have improved renal cell carcinoma (RCC) patient outcomes. However, complete remission (CR) with target agents is rare. Furthermore, CR of bone metastasis is much less common. We report a case of CR in bone and lung metastatic RCC. Radical nephrectomy...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimura, Akihiro, Nakata, Wataru, Yamamichi, Gaku, Tsujimura, Go, Tsujimoto, Yuichi, Nin, Mikio, Tsujihata, Masao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184521/
https://www.ncbi.nlm.nih.gov/pubmed/32368498
http://dx.doi.org/10.1016/j.eucr.2020.101213
_version_ 1783526600779759616
author Yoshimura, Akihiro
Nakata, Wataru
Yamamichi, Gaku
Tsujimura, Go
Tsujimoto, Yuichi
Nin, Mikio
Tsujihata, Masao
author_facet Yoshimura, Akihiro
Nakata, Wataru
Yamamichi, Gaku
Tsujimura, Go
Tsujimoto, Yuichi
Nin, Mikio
Tsujihata, Masao
author_sort Yoshimura, Akihiro
collection PubMed
description Target agents such as tyrosine kinase inhibitors have improved renal cell carcinoma (RCC) patient outcomes. However, complete remission (CR) with target agents is rare. Furthermore, CR of bone metastasis is much less common. We report a case of CR in bone and lung metastatic RCC. Radical nephrectomy was performed first, and clear cell RCC was diagnosed. Thereafter, sunitinib was started, and bone and lung metastases resolved entirely after 8 months of treatment. Sunitinib therapy was discontinued after 2 years because of the adverse event of proteinuria. However, the patient has remained in CR for over 1 year after sunitinib cessation.
format Online
Article
Text
id pubmed-7184521
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-71845212020-05-04 Complete remission of metastatic renal cell carcinoma to the bone with sunitinib Yoshimura, Akihiro Nakata, Wataru Yamamichi, Gaku Tsujimura, Go Tsujimoto, Yuichi Nin, Mikio Tsujihata, Masao Urol Case Rep Oncology Target agents such as tyrosine kinase inhibitors have improved renal cell carcinoma (RCC) patient outcomes. However, complete remission (CR) with target agents is rare. Furthermore, CR of bone metastasis is much less common. We report a case of CR in bone and lung metastatic RCC. Radical nephrectomy was performed first, and clear cell RCC was diagnosed. Thereafter, sunitinib was started, and bone and lung metastases resolved entirely after 8 months of treatment. Sunitinib therapy was discontinued after 2 years because of the adverse event of proteinuria. However, the patient has remained in CR for over 1 year after sunitinib cessation. Elsevier 2020-04-17 /pmc/articles/PMC7184521/ /pubmed/32368498 http://dx.doi.org/10.1016/j.eucr.2020.101213 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Oncology
Yoshimura, Akihiro
Nakata, Wataru
Yamamichi, Gaku
Tsujimura, Go
Tsujimoto, Yuichi
Nin, Mikio
Tsujihata, Masao
Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
title Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
title_full Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
title_fullStr Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
title_full_unstemmed Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
title_short Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
title_sort complete remission of metastatic renal cell carcinoma to the bone with sunitinib
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184521/
https://www.ncbi.nlm.nih.gov/pubmed/32368498
http://dx.doi.org/10.1016/j.eucr.2020.101213
work_keys_str_mv AT yoshimuraakihiro completeremissionofmetastaticrenalcellcarcinomatothebonewithsunitinib
AT nakatawataru completeremissionofmetastaticrenalcellcarcinomatothebonewithsunitinib
AT yamamichigaku completeremissionofmetastaticrenalcellcarcinomatothebonewithsunitinib
AT tsujimurago completeremissionofmetastaticrenalcellcarcinomatothebonewithsunitinib
AT tsujimotoyuichi completeremissionofmetastaticrenalcellcarcinomatothebonewithsunitinib
AT ninmikio completeremissionofmetastaticrenalcellcarcinomatothebonewithsunitinib
AT tsujihatamasao completeremissionofmetastaticrenalcellcarcinomatothebonewithsunitinib

Ejemplares similares